ClinicalTrials.gg

Program

LY3884961

A development code.

In Eli Lilly's pipeline, GBA1 gene therapy. Its studies are mostly in Parkinson Disease, led by Eli Lilly.

Furthest: phase 2, since Oct 14, 20191 company-led study, 1 open or runningNext primary completion: Aug 31, 2031 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly11 open or runningphase 2since Oct 14, 2019Oct 14, 2019Aug 31, 2031phase 2 · NCT04127578
  • Named in Eli Lilly’s own pipeline as GBA1 Gene Therapy, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 14, 2019First study: phase 2 study in Parkinson DiseaseFirst studyNCT04127578 · 32 enrolled · United States, Israel

Ahead

  1. Aug 31, 2031Primary completion: phase 2 study in Parkinson DiseaseNCT04127578

TargetBeta

“GBA1 gene therapy”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04127578Parkinson Disease · United States, Israel2Active, not recruitingAug 31, 203132

How it is read

Names in the registry

  • “LY3884961”, 1 entry

Codes read as this program: LY3884961.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.